ABSTRACT
Changes to manufacturing processes of propellant-based metered-dose inhalers
(pMDIs) due to the transition to hydrofluoroalkane-(HFA-) based formu
lations from chlorofluorocarbon-(CFC-) based systems are under way. These
changes are proceeding concurrently with reformulation efforts of the pMDI
systems themselves. In some cases, this may result in changes to the
formulation [1].
